In a lawsuit filed by the University of Missouri against a former professor, the doctoral student has an innovative and potentially profitable idea of purchasing a drug. The school says Ashim Mitra has patented the student's idea and sold it in a business that is potentially worth millions.
The period comes after months after the Food and Drug Administration has approved Cequa's dry-eye medicine, based on the work of the University's Dr. Kishore Cholkar, when he graduated from the University of Missouri at the University of Missouri. City Pharmacy.
Cequa, the school says, "is expected to compete for a significant portion of the multi-billion dollar annual market."
Curators at the University of Missouri sue Mitra, his wife and two pharmaceutical companies, accusing them of taking Cholkar's work. The school says owner of Cholkar's invention. Mitra and drug companies – Sun Pharmaceutical and Auven Therapeutics – are said to have been conserved to keep all their profits.
Mitra has already taken over $ 1.5 million from the drug, says the court, referring to Auven, a pharmaceutical company. When Mitra and Auven obtained a patent for the drug, the dress says Auven sold "all intellectual property for $ 40 million in salary and royalties to Sun Pharma, a large multinational pharmaceutical conglomerate."
"All this was done without publicity, not to mention the University's approval," the court.
In response to the litigation, Mitra sent a statement to the KCUR Member State, in which he called the university's statement "unexpected and disappointing." (KCUR is authorized by the Board of Trustees of the University of Missouri and is an editorially independent community service at the University of Missouri (Kansas City).)
Mitra said he could "clearly prove" that the ophthalmic breakthrough was "formulated by myself and the right co-authors".
"Dr. Kishore Cholkar is a successful student who wrote a document on other aspects of the cyclosporin preparation after the patent was submitted to the FDA for approval," said Mitra. "It is obvious that all UMCs are trying [to] enjoy the benefits of tireless work and others to succeed. "
The suit is also international, and Auven Therapeutics is listed in Virgin Islands, USA, in Switzerland. And says Sun Pharmaceutical Industries Ltd. is based in Mumbai, India.
The lawsuit claims that Auven is deliberately avoiding drug-related plans at a university outside of Mitra and that the company would have known that the professor had presented a "clear conflict of interest" with the court.
The curators at the University of Missouri are now asking the Federal Court to name Cholkar as the legal inventor of the patents for the drug and to declare the university's interest in the work at work. Mitra and the companies involved, as well as Mitra's wife, Ranjana, are also seeking compensation for both the pharmaceutical school and her husband in a consultancy business.
The school claims that Mitra, a professor at school who previously served in his patent committee, violated the terms of employment.
In August 1994, Mitra began working at the Missouri University-Kansas City Pharmacy School. He agreed to resign in January after conducting an internal investigation into possible violations of university education standards. Your resignation will be final on March 31, 2019.
In 2018, Mitra investigated allegations that her leverage as a teaching professor was being used to put pressure on students, especially Indian-speaking students, to do her job.
KCUR Laura Ziegler report last month:
"The Kansas City Star reported a report last autumn that he talked to dozens of students who claimed that Mitra threatened his students 'status, even the status of the students' visa, by refusing to do housework. at Indian cultural events, one student called the work "modern slavery."